|
|||||
|
|
Safety,tolerability and pharmacokinetics of rilpivirine following administration of a long‐acting formulation in healthy volunteers |
|
| Authors: | R Verloes S Deleu N Niemeijer H Crauwels P Meyvisch P Williams |
| Affiliation: | 1. Janssen Infectious Diseases BVBA, Beerse, Belgium;2. Janssen Clinical Pharmacology Unit, Merksem, Belgium |
| Abstract: | |
| Keywords: | HIV long‐acting formulation nonnucleoside reverse transcriptase inhibitor pharmacokinetics rilpivirine |